Loading
A phase 1 trial of CHM-029 run by Charm Therapeutics, now recruiting.
A Study of CHM-029 in Participants With NPM1 Mutated, KMT2A or NUP98 Rearranged AML is a phase 1 interventional study registered as NCT07751991 by Charm Therapeutics, with 40 participants planned, started 2026-09-28. Conditions recorded: AML (Acute Myeloid Leukemia). Interventions recorded: CHM-029.
Shares Acute myeloid leukaemia and the tag pipeline.
Shares Acute myeloid leukaemia and the tag pipeline.
Shares Acute myeloid leukaemia and the tag pipeline.
Shares Acute myeloid leukaemia and the tag pipeline.
Shares Acute myeloid leukaemia and the tag pipeline.
Shares Acute myeloid leukaemia and the tag pipeline.
Shares Acute myeloid leukaemia and the tag pipeline.
Shares Acute myeloid leukaemia and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/